Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study

About the Study

The Vanguard Study is looking at how multi-cancer detection (MCD) blood tests could fit into cancer screening. Adults ages 45-75 who do not have cancer will be randomly assigned to one of three groups. Everyone will have blood drawn at enrollment and again about 1 year later. The study also looks at questionnaires and what follow-up care happens after an abnormal result.

What the Study Involves

Participants will:

• Be randomly assigned to one of three groups. 
  • Group 1: blood is tested using the Shield multi-cancer detection (MCD) test at enrollment and again about 1 year later
  • Group 2: blood is tested using the Avantect multi-cancer detection (MCD) test at enrollment and again about 1 year later
  • Group 3: participants will have blood drawn at enrollment and again about 1 year later, but no MCD testing will be performed as part of the study.
• Complete questionnaires during the study (for example, about health history, demographics, and cancer screening behaviors).
• If you have an abnormal (positive) MCD result, your study team and health care team will guide next steps. Follow-up testing may be needed to find out whether cancer is present.
• Continue routine cancer screening recommended for your age and risk factors.

Time commitment: Participation lasts up to about 2 years, including questionnaires and follow-up.

People may be eligible if they:

• Are between 45 and 75 years old
• Do not currently have cancer
• Can complete questionnaires during the study
• Can return for a second blood draw about 1 year after enrollment

People who:

• Had a solid tumor or blood cancer diagnosis (with or without treatment) within the last 5 years
• Are currently being evaluated for possible cancer (for example, you have upcoming tests to find out whether you have cancer)
• Are currently pregnant or breastfeeding, or plan to become pregnant in the next year